We would love to hear your thoughts about our site and services, please take our survey here.
PW - thanks for posting the article, which helps describe the scale of the STI problem.
I haven't been able to shake the thought that somehow these new partners might have come through Senzo. This latest RNS says we have been working with them for 12 months, we announced the Senzo partnership almost 12 months ago to the day, and both the new partners and Senzo are based in the US.
https://www.senzo.com/newsroom/senzo-and-abingdon-health-enter-into-strategic-partnership
So this might also be interesting. Its a blog from Senzo about STI's which again details the scale of the problem and highlights that getting LFT sensitivity levels up when looking at STI conditions has been the main headwind in development. Of course, the whole point of Senzo is to increase sensitivity to PCR levels through its ALF tech.
https://static1.squarespace.com/static/63174674e5302f1a8f9e9dbc/t/659ae1c8fc1f77528ed44d4b/1704649165514/FDX+-+STI%28s%29.pdf
It does worry me that I can't find anything about our new partners, and nor have ABDX put out anything on their media feeds about this news so they're not screaming it from the rooftops - I have written to ABDX to see if they can give me anything more. But if we are looking at an LFT for STI's that meets required sensitivity thresholds then the market looks massive. And of course, by buying into a US based company we are getting a foothold in that jurisdiction.
I think the latter also.
Heās essentially making a growth acquisition from cash flow, without a raise. The fact he feels able to do that, just a week or so after confirming no raise expectation in 2024 and given his laser focus on cash flow break even, strengthens my belief that current revenues and forecasts are more than just robust.
True, assuming the Ā£500k all relates to future cost, and not cost already accrued.
Either Yates has been forced to take equity because thereās no cash, or he wants to take equity. If the latter, then it suggests strongly that he sees real growth potential in the project and expects it to accelerate progress to cash break even and beyond
Donāt really know what to make of this - scattergun thoughts are;
I can find nothing about Devyn LLC, Find Out From Home LLC, or Yannick Namia, which is odd.
The āLLCā suggests theyāre US companies. Thatās been a real growth area for us.
A Ā£500k stake for 23% values FOFH LLC at over Ā£2m. Not bad for a new unproven enterprise.
Are we investing because we want to, or because they canāt pay the fee? Great if the former - suggests real enthusiasm and potential.
Iām wondering if these new tests might be molecular or based on Senzo ALT tech
Honestly, on the face of it it looks great, but itās difficult to add colour because thereās little else to go on.
As an aside, itās interesting they brought the interims forward only to announce a succession of news thereafter.
Yup. Weāve spent the last couple of years rebuilding on a prudent fee for service model, diligently growing our quality customer base. Through 2024 we will see more and more customers commercialising and requiring manufacture. That hopefully will produce a regular and growing annuity income from which further growth can be funded.
This thing sells itself imo. We just need more investors to look under the bonnet, but Iām happy to keep accumulating until they do.
A bit more colour to the ABDX proposition
https://www.abingdonsimplytest.com/own-brand-diagnostics-products-navigating-challenges/
ABDX certainly now pushing this OEM/private label as a new service to retailers
https://www.abingdonsimplytest.com/knowledge-centre/private-own-label-solutions/
This one, from the Co-owner and Director of Crest Medical makes for interesting, and potentially exciting, reading.
ā Delighted to have developed and worked with Abingdon Health plc and Boots UK on these two diagnostic tests ā¦ keep an eye out over the next few weeks for the next launch of a revolutionary test!!ā
Does he mean another test in conjunction with ABDX - fair bet I think.
https://www.linkedin.com/posts/matthew-courtney-5ab14879_boots-to-sell-its-first-own-brand-self-tests-activity-7176600829678755841-nZVW?utm_source=share&utm_medium=member_desktop
JT - just wondering, but do you think the safety and tolerability results in the AVA6000 trial will mean future trials using the platform could start at higher doses than might otherwise be standard in trial protocols, thus reducing trial timescales?
I hadnāt looked for a while, but seems to me that all of the tests on the AST site have had a branding makeover, and now look like more like proper retail offerings as opposed to medical supplies.
And noticeably, two of the tests now have a very retail oriented instruction for use video - you guessed it, Vitamin D and Iron Deficiency.
Would appreciate anyone's help on something.
As far as I understand it, Boots are effectively going to be white labelling Abingdon Simply Test products. We make them, they buy them from us at a margin, they stick their branded packing around them (or we may do it for them) and they sell them to retail for a margin.
So where does "our partner" Crest Medical fit in? Ae they someone we've made a distribution agreement with, and they are distributing to Boots?
I don't know if it really matters too much apart from the fact that presumably Crest want some piece of the pie.
Thanks
For info - an insight into what industry thinks about the Boots move
https://www.linkedin.com/posts/fernando-ammann-2b697698_healthcare-technology-innovation-activity-7176302251865432064-xh6L?utm_source=share&utm_medium=member_desktop
Interesting thanks. Iāll have to do some more reading!
Imagine 75 years ago. You have a stock with normal price movements and so, according to pure theory, it should be possible to predict which way the crowd will turn. But nobody knows the technical indicators because thereās no tools to do it. So absent that knowledge, would the crowd still turn the same way as they might today?
Charting seems just as much a contributor to price movements these days as it is a measure of it. But then thatās a bit moot if all you really want to know, regardless of why, is which way the herd will turn. Thatās the real value of charting imo.
For awareness, from a gov publication on 3/3/24
ā The Chancellor is also confirming that companies will soon be able to apply for a share of the Ā£520 million funding for life sciences manufacturing announced at Autumn Statement, with competitions for large scale investments opening for expressions of interest this summer and medium and smaller sized companies in the autumn. The fund is designed to build resilience for future health emergencies such as influenza pandemics and capitalise on the UKās world-leading research and development.ā
https://www.gov.uk/government/news/360-million-to-boost-british-manufacturing-and-rd
Donāt know if this is something ABDX might consider.
Thanks!
Iāve never understood how price action in and of itself can tell you whatās most likely to happen. For me SP movements are simply a function of supply/demand; what happens based on technical considerations is almost self fulfilling because there will be a weight of enthusiasts, in our case identifying resistance has been broken, who together weight trading to either the demand or supply side based on that technical indication and so drive the price in the direction they all āpredictedā. But Iām sure thatās just naive/ignorant!
Letās see what tomorrow brings
Wyndrum, at the close we had a spread of 8.6 - 9.5, so the mid price was 9.05. This was the case even though dummy sells gave a 9.375 quote.
We only closed at 9.5 because of the uncrossing trade (the auction was interesting BTW with plenty of interest on the buy side). So, unless we get another RNS tomorrow, we will open at 9.05 and not 9.5.
Can I ask, from a charting perspective (which I know nothing about), is it the actual 9.05 close or the 9.5 UT that's relevant?
Thanks in advance
i jotted down who we know we're working with, and who i suspect we are. thought it might help others so posting. ignore as you wish!!
salistick - in sd, tesco, launched in israel, sweden, norway, uk (know)
52 north - neutropenic sepsis - part of idap. going through clinical. in major us initiatives (known)
upfront - lv0 stroke test - part of idap. going through final clinical. ukca hoped for very shortly (known)
condiia bioscience - fuel testing for aviation. (very strongly suspect)
venomaid - test for early diagnosis of correct snakebite (suspect)
folium science - swiftr test to quickly identify salmonella in chickens (pretty relevant given recent news on poland) recently launched in brazil (very strongly suspect)
nib biotec - test for prostate cancer. clinical results to be announced imminently (strongly suspect)
loop diagnostics - septiloop sepsis test (known)
nordixdx - rapid aquaculture test for use in fish farms (suspect)
abingdon simply test range (known)
axxinbio - using our pcrd product in their natflow molecular amplification system. (known)
hormona - ****ne test (known)
ecoflow - environmentally friendly cassette, testing prototypes h2 2024
vjj - vaginal health test (mildly suspect)
protak scientific - enzyme indicators to measure bio-decontamination efficacy (strongly suspect, might even know but cant remember)
zoetis - animal health tests for worlds largest animal health company. certain we have been supplying them for a while.
senzo collaboration
possible continuing collaboration with mhc (previously concepta) for development support and manufacturing.
i don't think this goes even halfway to the 29 projects we know we are working on. as i say, ignore as you wish.